Clinical trial NCT00242320: Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)
Official title: The JADE Study: A 12-week, Double-blind, Randomized Study to Investigate the Effect of 500 mcg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: COPD
Keywords: COPD
chronic obstructive pulmonary disease
Roflumilast
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-10-20
Enrollment: 551
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the effect of roflumilast on lung function in patients with COPD. Roflumilast will be administered orally once daily in the morning at one dose level. The study duration consists of a baseline period (4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and tolerability of roflumilast.


Eligibility criteria: Main Inclusion Criteria:

* Written informed consent
* Patients with a history of chronic obstructive pulmonary disease (COPD) as defined by the GOLD criteria (2003)
* FEV1/FVC ratio (post bronchodilator) smaller or equal 70%
* FEV1 (post bronchodilator) 30-80% of predicted
* Fixed airway obstruction
* Current smoker or former smoker (smoking cessation at least one year ago) with a smoking history of at least 10 pack years
* Clinically stable COPD within 4 weeks prior to baseline visit
* Availability of a chest x-ray

Main Exclusion Criteria:

* COPD exacerbation indicated by a treatment with systemic glucocorticosteroids
* Lower respiratory tract infection
* Diagnosis of asthma
* Known alpha-1-antitrypsin deficiency
* Need for long term oxygen therapy defined as longer or equal 16 hours/day
* Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)
* Known infection with HIV, active hepatitis and/or liver insufficiency (according to the Child Pugh score A or worse)
* Diagnosis or history of cancer
* Clinically significant cardiopulmonary abnormalities
* Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial
* Female patients of childbearing potential, not using reliable method of contraception for the entire study duration, post-menopausal \> 1 year or who are not using any other method considered sufficiently reliable by the investigator in individual cases
* Participation in another study (use of investigational product) within 30 days preceding the baseline visit or re-entry of patients already enroled in this trial
* Alcohol or drug abuse
* Inability to follow the study procedures due to e.g., language problems, physiological disorders
* Use of not allowed drugs
* Suspected hypersensitivity to the study medication or rescue medication

Primary outcomes:
measure: mean change from randomization to endpoint in lung function (post bronchodilator)
timeFrame: 12 weeks
Secondary outcomes:
measure: mean change from randomization to endpoint in pre and post bronchodilator spirometric parameters
timeFrame: 12 weeks
measure: exacerbation rate
timeFrame: 12 weeks
measure: adverse events
timeFrame: 12 weeks
measure: changes in laboratory values
timeFrame: 12 weeks
measure: changes in vital signs
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Altana Pharma/Nycomed
city: Shatin, NT, Hong Kong
country: Hong Kong
facility: Altana Pharma/Nycomed
city: Anvang-Si, Gveonggi-Do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Chungbuk
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Gangwon-do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Gangwon-Do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Gwangju
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Gyeonggi-do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Jiniu-Si. Gveongsangnam-Do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Seoul
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Uijongbu-city, Gveonggi-Do
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Ulsan
country: Korea, Republic of
facility: Altana Pharma/Nycomed
city: Jalan Rasah, Seremban
country: Malaysia
facility: Altana Pharma/Nycomed
city: Kota Bharu / Kelantan
country: Malaysia
facility: Altana Pharma/Nycomed
city: Kota Kinabalu, Sabah
country: Malaysia
facility: Altana Pharma/Nycomed
city: Kuala Lumpur
country: Malaysia
facility: Altana Pharma/Nycomed
city: Kuala Lumpur
country: Malaysia
facility: Altana Pharma/Nycomed
city: Kuala Lumpur
country: Malaysia
facility: Altana Pharma/Nycomed
city: Manila
country: Philippines
facility: Altana Pharma/Nycomed
city: Quezon City
country: Philippines
facility: Altana Pharma/Nycomed
city: Quezon City
country: Philippines
facility: Altana Pharma/Nycomed
city: Quezon City
country: Philippines
facility: Altana Pharma/Nycomed
city: Quezon City
country: Philippines
facility: Altana Pharma/Nycomed
city: Kaohsiung
country: Taiwan
facility: Altana Pharma/Nycomed
city: Taipei City 114
country: Taiwan
facility: Altana Pharma/Nycomed
city: Taipei
country: Taiwan
facility: Altana Pharma/Nycomed
city: Taipei
country: Taiwan
facility: Altana Pharma/Nycomed
city: Tau-Yuan
country: Taiwan
facility: Altana Pharma/Nycomed
Study officials:
affiliation: AstraZeneca
name: AstraZeneca AstraZeneca
role: STUDY_DIRECTOR
References: